This meta-analysis from two nationwide cohorts indicates that SSRI and SNRI augmentation therapies for people with ...

Baxdrostat, which AstraZeneca acquired in a 2023 buyout of CinCor Pharma, could become a new treatment for people whose ...

In this GEN webinar, Dave Lahr, PhD, Senior Director of Bioinformatics at Foghorn Therapeutics, discusses chromatin regulation and epigenetic mechanisms that shape transcriptional responses to ...

Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA ® (vonoprazan ...

Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA ® (vonoprazan ...

We present preclinical data supporting the mechanism of action of detalimogene voraplasmid, which involves immune cell recruitment, tumor microenvironment remodeling and immune training on neoantigens ...

A triple therapy of vonoprazan, amoxicillin and bismuth potassium citrate achieved an eradication rate of just over 90%, similar to that of the standard quadruple therapy, in patients with ...